Acadia Healthcare Company, Inc. - Common Stock (ACHC)
29.66
+0.85 (2.95%)
Acadia Healthcare Company is a leading provider of behavioral healthcare services, specializing in the treatment and management of mental health and substance use disorders
With a network of facilities across the United States, Acadia operates a range of inpatient and outpatient programs designed to deliver high-quality care tailored to the unique needs of individuals facing psychological challenges. The company is committed to improving patient outcomes through evidence-based practices, compassionate treatment approaches, and a focus on fostering a supportive recovery environment. Acadia's mission is to enhance the overall well-being of its patients and communities by providing accessible and effective mental health solutions.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at HCA Healthcare (NYSE:HCA) and its peers.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the hospital chains industry, including Universal Health Services (NYSE:UHS) and its peers.
Shares of behavioral health company Acadia Healthcare (NASDAQ:ACHC)
fell 24.1% in the afternoon session after the company reported weak fourth quarter results: Its revenue guidance for next quarter missed significantly and its EPS fell short of Wall Street's estimates. Overall, this was a softer quarter.
Behavioral health company Acadia Healthcare (NASDAQ:ACHC) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.2% year on year to $774.2 million. Next quarter’s revenue guidance of $770 million underwhelmed, coming in 5.8% below analysts’ estimates. Its non-GAAP profit of $0.64 per share was 10.4% below analysts’ consensus estimates.
Shareholders of Acadia Healthcare would probably like to forget the past six months even happened. The stock dropped 43.2% and now trades at $41.25. This was partly due to its softer quarterly results and might have investors contemplating their next move.
KeyBanc anticipates healthcare services stocks will thrive in 2025, with growth driven by higher patient volumes and improving Medicare Advantage policies.
Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.
